CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus

Official title

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)

Overview

This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE). Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.

Detailed description

Lupus disease activity is associated with increased numbers of activated naïve B cells and polyclonal expansion of antibody secreting cells, indicating a central role for B cells in the pathogenesis of SLE. While traditional anti-CD19 antibody therapies have been utilized with varying success in the treatment of Systemic lupus erythematosus (SLE), CD19 directed cellular therapies have emerged as an attractive therapeutic option that may lead to immunosuppression-free remission in this population given the ability of CD19 directed CAR T cells to more deeply deplete the B cell compartment. Previous clinical experience utilizing CD19 directed CAR T cells in patients diagnosed with Systemic lupus erythematosus (SLE) have exceeded any other Systemic lupus erythematosus (SLE) therapeutic available; although, those clinical trials have treated a limited number of subjects. During this trial the test article will be CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.

Interventions

• Biological CART19
  CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv:41-BB:TCRζ, administered by IV injection.

Primary outcome measures

• Frequency of the dose limiting toxicities of CART19 [Time frame: up to 24 months post infusion]

Secondary outcome measures (9)

• Rate of childhood SLE Clinical Remission off steroids (cCR-0) at 3 months [Time frame: 3 months post treatment]
• 2-year overall survival rate [Time frame: 24 months post infusion]
• 2-year flare free survival rate [Time frame: up to 24 months post infusion]
• Feasibility of manufacturing CART19 for participants with SLE [Time frame: up to 24 months post infusion]
• Proportion of patients achieving a complete renal response [Time frame: up to 24 months post infusion]
• Proportion of patients achieving a partial renal response [Time frame: up to 24 months post infusion]
• Rate of CART19 expansion, persistence or B cell aplasia [Time frame: up to 24 months post infusion]
• Survival of CART19 cells [Time frame: up to 24 months post infusion]
• Elevations in cytokines in serum [Time frame: up to 24 months post infusion]

Eligibility criteria

Inclusion criteria

• Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.
• Patient age must be 12-29 years, inclusive, at time of enrollment.
• Meeting ACR/EULAR Classification Criteria for SLE
• ANA positive > 1:80 and/or double-stranded DNA (dsDNA) positive
• Active (refractory) disease, defined as follows:

a. Lupus nephritis subjects must meet both the following criteria: i. ISN/RPS active nephritis Class III/IV +/- V lupus nephritis diagnosed by biopsy within past 12 months.

ii. Persistent and clinically significant: ≥2 measurements with urine protein with either of the following:

• > 1mg/mg creatinine
• > 0.5 mg/mg creatinine associated with renal dysfunction or low albumin.
• > 0.5 mg/mg creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg/day or 0.15mg/kg/day, whichever is lower, due to active disease.

6\. Patients must have had at least 3 months of cumulative conventional therapy defined as:

• Conventional induction immunosuppressive agent(s) (e.g., mycophenolate mofetil, cyclophosphamide), and
• At least one additional therapy:

i. B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor) 7. Adequate organ function status

• Renal: eGFR must be ≥30 and subject cannot be receiving dialysis.
• Hepatic: Transaminases < 5x upper limit of normal and serum conjugated (Direct) bilirubin <1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C.
• Cardiac: Shortening fraction > 28%, left ventricular ejection fraction >45%, and no evidence of severe pulmonary hypertension
• Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and <Grade 3 hypoxia; DLCO ≥40% (corrected for anemia and/or VA volume if necessary) if PFTs are clinically appropriate as determined by the treating investigator.

8\. Subjects of reproductive potential must agree to use acceptable birth control methods.

Exclusion criteria

• Active, untreated infections
• HIV infection
• Active Hepatitis B

a. Patients must have a negative hepatitis B surface antigen to be enrolled on this study.

• Active Hepatitis C
• Patients with severe neuropsychiatric lupus or neurologic manifestations of SLE (e.g. stroke, seizure, psychosis, demyelinating syndromes, organic brain syndrome, or lupus related headaches)
• Monogenic lupus (known)
• Previous autologous or allogenic stem cell transplant
• Previous kidney transplant
• History of seizure disorder
• Patients who are on anti-epileptic therapy
• Participation in a clinical trial in which the patient receives an investigational drug within a time period equal or less than 5.5 half-lives of the investigational agent prior to study enrollment.
• Subjects who are unwilling or unable to discontinue immunosuppressive medications at the times of CART19 infusion will be excluded from the trial
• Any comorbidity that in the opinion of the investigators would jeopardize the ability of the subject to tolerate therapy.
• Pregnant patients. All participants of childbearing potential must have negative pregnancy test.
• Lactating participants who want to continue breastfeeding.
• Patients who are unwilling to consent to LTFU

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Children's Hospital of Philadelphia — Philadelphia

Identifiers

NCT: NCT06839976 · 24-022668

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗